Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
Autore:
Kosmas, C; Tsavaris, N; Vadiaka, M; Stavroyianni, N; Koutras, A; Malamos, N; Onyenadum, A; Rokana, S; Polyzos, A; Kalofonos, HP;
Indirizzi:
Helena Venizelou Hosp, Med Oncol Unit, Dept Med, GR-16341 Athens, Greece Helena Venizelou Hosp Athens Greece GR-16341 ed, GR-16341 Athens, Greece Univ Athens, Sch Med, Laikon Gen Hosp, Dept Pathophysiol,Oncol Unit, GR-11527 Athens, Greece Univ Athens Athens Greece GR-11527 l,Oncol Unit, GR-11527 Athens, Greece Univ Hosp Patras, Dept Med, Oncol Unit, Rion, Greece Univ Hosp Patras Rion Greece Patras, Dept Med, Oncol Unit, Rion, Greece Univ Athens, Sch Med, Laikon Gen Hosp, Dept Propedeut Med, GR-11527 Athens, Greece Univ Athens Athens Greece GR-11527 ropedeut Med, GR-11527 Athens, Greece
Titolo Testata:
CANCER
fascicolo: 11, volume: 92, anno: 2001,
pagine: 2902 - 2910
SICI:
0008-543X(200112)92:11<2902:GADASC>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II TRIAL; COMBINATION CHEMOTHERAPY; MULTICENTER TRIAL; RANDOMIZED TRIAL; SUPPORTIVE CARE; CLINICAL-TRIALS; CANCER; CISPLATIN; IFOSFAMIDE; VINORELBINE;
Keywords:
nonsmall cell lung carcinoma; gemcitabine; docetaxel; paclitaxel;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Kosmas, C Helena Venizelou Hosp, Med Oncol Unit, Dept Med, 21 Apollonlou St, GR-16341 Athens, Greece Helena Venizelou Hosp 21 Apollonlou St Athens Greece GR-16341 e
Citazione:
C. Kosmas et al., "Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens", CANCER, 92(11), 2001, pp. 2902-2910

Abstract

Background. Treatment options for patients with recurrent nonsmall cell lung carcinoma (NSCLC) remain limited as a result of poor activity of older agents after platinum-based therapy. In the current Phase II study, the authors evaluated the combination of gemcitabine and docetaxel in patients withrecurrent NSCLC. Methods. Patients with advanced NSCLC (Stage IIIB-IV) a World Health Organization performance status (PS)less than or equal to2, prior paclitaxel plus platinum-based chemotherapy, and unimpaired hematopoietic and organ function were eligible. Chemotherapy was administered as follows: gemcitabine 1000 mg/m(2) was administered on Days 1 and 8 followed by docetaxel 100 mg/m(2) on Day 8, and this regimen was recycled every 21 days. Prophylactic granulocyte-colony stimulating factor was administer ed on Days 10-14 or until the patient achieved a white blood cell count greater than or equal to 5000/muL. Results. Of 43 patients who were entered on the study, 41 patients were evaluable for response, and all were evaluable for toxicity. The median patient age was 63 years (range, 47-70 years), the median PS was 1 (range, 0-2),there were 38 male patients, and there were 5 female patients. Four patients had Stage IIIA disease, 17 patients had Stage IIIB disease, and 22 patients had Stage IV disease. Histologies included 19 patients with adenocarcinoma, 18 patients with squamous cell carcinoma, and 3 patients with large cell carcinoma. Metastatic sites included lymph nodes in 28 patients, bone in6 patients, liver in 5 patients, brain in 5 patients, lung nodules in 8 patients, adrenals in 7 patients, and other sites in 3 patients. All patientshad received prior paclitaxel plus platinum-based treatment; 28 patients had received prior paclitaxel, ifosfamide, and cisplatin. Objective responses were partial response (PR) in 14 of 43 patients [33%; 95% confidence interval [95%CI], 18.5-46.6%], stable disease (SD) in 16 of 43 patients (37%; 95% CI, 22.8-51.6%), and progressive disease (PD) in 13 of 43 patients (30%;95% CI, 16.3-43.7%). The median time to disease progression was 6 months (range, 1.0-20.0+ months), and the median survival was 8.5 months (range, 1.5-20.0+ months). The 1-year survival rate was 28%. Grade 3-4 neutropenia was experienced by 53% of patients (30% Grade 4), with 14% of patients experiencing febrile neutropenia. Grade 3 thrombocytopenia was experienced by 7% of patients (no Grade 4), whereas other Grade 3 nonhematologic toxicities were never encountered. Conclusions. The combination of gemcitabine and docetaxel is active and iswell tolerated in patients with advanced NSCLC who have failed prior taxane plus platinum chemotherapy. This regimen represents a tolerable and effective combination to apply in the palliative treatment of patients with recurrent NSCLC. Cancer 2001;92:2902-10. (C) 2001 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 20:55:13